Latest Breaking News On - National reimbursement drug list - Page 4 : vimarsana.com

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
koreabizwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from koreabizwire.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoZhi liJunshi biosciencesJunshipharma junshi biosciencesPabout toripalimabShanghai junshi biosciences co ltdAustralia therapeutic goods administrationPr teamEuropean medicines agencyUniversity cancer hospitalSingapore health sciences authorityNational medical products administrationInternational metastatic renal cell carcinoma database consortiumNational reimbursement drug listIr team

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Rhui zhouUnited statesHong kongMichael shiEli lillyInnovent biologicsAdimab incyteMd anderson cancer centerChina limitedPrnewswire innovent biologics incThejournal of the american medical associationNational reimbursement drug listChina national reimbursement drug listChina national medical products administrationNew drug applicationSenior vice president

China Medical System （867 HK）2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs

China Medical System （867 HK）2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Junshi biosciencesNational volume based procurement theChina medical system holdings ltdRxilient healthNational reimbursement drug listChina medical systemNational volume based procurementDiazepam nasal sprayTildrakizumab injectionMethotrexate injection psoriasisSucroferric oxyhydroxide chewable tabletsMethotrexate injectionHighly selectiveMedical aesthetic businessPolyl lactic acid microparticle filler injectionPolycaprolactone microsphere gel

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated

— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients —

Hong kongUnited statesAtholl tweedieZhou yiBen atwellSingle institution studyAmerican cancer societyStock exchange of hong kongChina national medical products administrationExchange commissionEuropean lung cancer congress onEuropean lung cancer congressNational reimbursement drug listWorld health organizationChina limitedInternational agency for research on cancer

China Medical System （867 HK）2023 Annual Results: Despite

China Medical System （867 HK）2023 Annual Results: Despite
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Junshi biosciencesChina medical system holdings ltdNational volume based procurement theRxilient healthNational reimbursement drug listChina medical systemNational volume based procurementDiazepam nasal sprayTildrakizumab injectionMethotrexate injection psoriasisSucroferric oxyhydroxide chewable tabletsMethotrexate injectionHighly selectiveMedical aesthetic businessPolyl lactic acid microparticle filler injectionPolycaprolactone microsphere gel